7:10 - 7:45 am | Keynote: Anti-body builders for lower middle income countries | Dr. Nataša Skoko
International Centre for Genetic Engineering and Biotechnology, Italy |
7:45 - 8:00 am | Genetics of the human TMPRSS2 regulates COVID-19 infection and Arbidol as a potential drug in COVID-19 patient viral clearance | Naveen Vankadari
University of Melbourne, Australia |
8:00 - 8:15 am | COVID-19 mRNA vaccination drives differential mucosal neutralising antibody profiles in naïve and SARS-CoV-2 previously infected individuals | Stephanie Longet
University of Oxford, United Kingdom |
8:15 - 8:30 am | Secondary bacterial infections in lymphatic filariasis patients: implications of multi-drug resistance | Bill C. Aglomasa
Kwame Nkrumah University of Science and Technology, Ghana |
8:35 - 8:50 am | Exploring nuclear, viral capsid, and early antigen proteins: An immunoinformatic approach to designing an Epstein Barr Virus Type 1 and 2 vaccine | Taiwo O. Ojo
Helix Biogen Institute, Ladoke Akintola University of Technology, Nigeria |
8:50 - 9:05 am | Antimicrobial peptides against multidrug-resistant pseudomonas aeruginosa biofilm from cystic fibrosis patients | Daniel Ben Hur
Weizmann Institute of Science, Israel |
9:05 - 9:20 am | Implantable, battery-free, Bluetooth-enabled, multiwavelength spectroscopy device for the remote monitoring of physiological biomarkers | Anat Usatinsky
University of Toronto, Canada |
9:20 - 9:35 am | HotDoc: Use of digital technologies to enhance capacity building in Sub-Saharan Africa: The International Cancer Institute model | Pavanraj Chana
International Cancer Institute, Kenya |
9:35 - 9:45 am | Break | |